Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors

被引：23

作者：

Hedner, U. ^{[1
]}

机构：

[1] Lund Univ, Lund, Sweden

[2] Novo Nordisk AS, Res & Dev, DK-2820 Gentofte, Denmark

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2006年 / 4卷 / 11期

关键词：

D O I：

10.1111/j.1538-7836.2006.02166.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2498 / 2500

页数：4

共 24 条

[1]

Ahlberg A., 1965, Acta Orthop, V36, P3, DOI [10.3109/ort.1965.36.suppl-77.01, DOI 10.3109/ORT.1965.36.SUPPL-77.01]

[2]

ALMUS FE, 1990, BLOOD, V76, P354

[3]

BAUER KA, 1989, BLOOD, V74, P2007

[4]

BAUER KA, 1990, BLOOD, V76, P731

[5] Optimizing factor prophylaxis for the haemophilia population: where do we stand? [J].

Blanchette, VS ;

Manco-Johnson, M ;

Santagostino, E ;

Ljung, R .

HAEMOPHILIA, 2004, 10 :97-104

[6] Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures [J].

Cooper, HA ;

Jones, CP ;

Campion, E ;

Roberts, HR ;

Hedner, U .

HAEMOPHILIA, 2001, 7 (05) :517-522

[7] The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX [J].

He, S ;

Blombäck, M ;

Ekman, GJ ;

Hedner, U .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (06) :1215-1219

[8] Clinical use of recombinant FVIIa (rFVIIa) [J].

Hedner, U ;

Ingerslev, J .

TRANSFUSION SCIENCE, 1998, 19 (02) :163-176

[9]

Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009

[10]

Ingerslev J, 1996, HAEMOSTASIS, V26, P118

← 1 2 3 →